Rep. Gilbert Cisneros Buys Shares of Vaxcyte, Inc. (PCVX)
U.S. Rep. Gilbert Cisneros disclosed a purchase of Vaxcyte shares valued between $1,001 and $15,000.
Financial Disclosure Report
Clerk of the House of Representatives • Legislative Resource Center • B81 Cannon Building • Washington, DC 20515
Filer Information
- Name:
- Rep. Gilbert Cisneros (D-CA)
- Status:
- Member — House
- State/District:
- CA-31
Filing Information
- Filing Type:
- Periodic Transaction Report
- Filing Year:
- 2026
- Filing Date:
- Jun 9, 2026
Schedule B: Transactions
| Asset | Transaction | Date | Amount |
|---|---|---|---|
| Vaxcyte, Inc. ($PCVX) | Buy | May 13, 2026 | $1,001 - $15,000 |
Key Points
- U.S. Representative Gilbert Cisneros bought Vaxcyte shares valued between $1,001 and $15,000, as disclosed on June 9, 2026.
- Vaxcyte, Inc. trades on NasdaqGS under the ticker PCVX, with a market cap of $6.85 billion and a 52-week range between $29.08 and $65.00.
- Major institutional holders like Janus Henderson and BlackRock have also adjusted their positions in Vaxcyte recently.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
On June 9, 2026, U.S. Representative Gilbert Cisneros disclosed a purchase of Vaxcyte, Inc. shares on NasdaqGS under the ticker PCVX. The transaction, which took place on May 13, 2026, was valued between $1,001 and $15,000. This disclosure comes as part of the STOCK Act requirements for Congressional members.
Gilbert Cisneros vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
Other Institutional Activity in Vaxcyte
Several institutional investors have been active in Vaxcyte, Inc. Janus Henderson Group PLC increased its holdings by 3,188,687 shares, bringing its total to 16,575,875 shares valued at approximately $960.2 million. FMR LLC also boosted its position by 2,658,347 shares, ending with 16,492,861 shares worth about $958.4 million. T. Rowe Price Investment Management, Inc. added 829,684 shares, resulting in a total of 12,126,017 shares valued at $704.6 million. RA Capital Management, L.P. and BlackRock, Inc. both made smaller additions of 750,000 and 725,438 shares, respectively.
Vaxcyte, Inc. Stock Down 17.6%
Shares of Vaxcyte, Inc. (NasdaqGS: PCVX) traded near $47.46. The company has a market cap of approximately $6.85 billion. Vaxcyte is not currently profitable, so it doesn't have a meaningful P/E ratio. The stock's 52-week range is between $29.08 and $65.00, with a 50-day moving average of $54.48 and a 200-day moving average of $48.67. The company's beta is 1.242, indicating moderate volatility compared to the broader market.
$PCVX stock price
Daily closing prices, year to date. Not investment advice.
Insider Buying and Selling at Vaxcyte, Inc.
Recent insider activity at Vaxcyte includes several planned sales by Chief Operating Officer Jim Wassil, who sold 2,250 shares at prices ranging from $49.52 to $58.43 between April and June 2026. Additionally, Elvia Cowan, SVP of Finance & CAO, sold 3,000 shares at $60.00 on April 7, 2026, in a planned transaction.
Analysts Set New Price Targets
On February 26, 2026, BTIG maintained its buy rating on Vaxcyte with a price target of $89.00. Earlier, on February 2, 2026, Guggenheim reiterated its buy rating with a target of $116.00. Needham also maintained a buy rating on January 7, 2026, setting a target of $110.00. Analysts' consensus reflects a strong buy recommendation with an average target price of $109.00.
About Vaxcyte, Inc.
Vaxcyte, Inc. is a biotechnology company based in San Carlos, California. The company is focused on developing vaccines to prevent or treat bacterial infectious diseases. Its lead product, VAX-24, is designed to prevent invasive pneumococcal disease in infants. Vaxcyte also has several other vaccine candidates in various stages of development. The company, led by CEO Grant E. Pickering, employs around 507 people.
Bottom Line
The purchase by Gilbert Cisneros highlights ongoing interest in Vaxcyte, Inc., a company actively engaged in vaccine development. While 13F filings and Congressional disclosures are backward-looking, they offer insights into investment trends and institutional confidence. Investors often track these moves to gauge market sentiment, but it's important to remember these filings may not reflect the most current positions.
Get Vaxcyte, Inc. alerts
New 13F filings, insider trades, and analyst moves on $PCVX, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.